Senti Biosciences, Inc. (NASDAQ:SNTI) Given Consensus Recommendation of “Moderate Buy” by Analysts

Senti Biosciences, Inc. (NASDAQ:SNTI) has been given an average rating of “Moderate Buy” by the five brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $9.00.

A number of research firms have recently commented on SNTI. Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a report on Thursday, January 22nd. Leerink Partners assumed coverage on Senti Biosciences in a research note on Friday, November 21st. They set an “outperform” rating and a $6.00 target price on the stock. Chardan Capital boosted their price target on Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Finally, Wall Street Zen raised Senti Biosciences to a “sell” rating in a report on Saturday, December 13th.

Institutional Trading of Senti Biosciences

A number of institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in shares of Senti Biosciences during the fourth quarter valued at approximately $46,000. Jane Street Group LLC bought a new stake in Senti Biosciences in the 4th quarter worth approximately $40,000. Citadel Advisors LLC purchased a new stake in Senti Biosciences during the 3rd quarter valued at $117,000. Armistice Capital LLC bought a new position in shares of Senti Biosciences during the 2nd quarter valued at $1,883,000. Finally, Geode Capital Management LLC boosted its stake in shares of Senti Biosciences by 395.6% in the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after buying an additional 117,588 shares during the last quarter. Hedge funds and other institutional investors own 25.70% of the company’s stock.

Senti Biosciences Price Performance

Shares of Senti Biosciences stock opened at $0.94 on Friday. Senti Biosciences has a 1 year low of $0.80 and a 1 year high of $5.10. The firm’s 50-day moving average is $1.01 and its 200 day moving average is $1.46. The stock has a market cap of $24.82 million, a price-to-earnings ratio of -0.28 and a beta of 2.13.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.